Diabetic nephropathy is defined by the presence of proteinuria, and it is a form of chronic kidney disease that occurs when the kidney is exposed to persistent hyperglycemia. It affects approximately 20-40% of patients with diabetes mellitus. The risk of diabetic nephropathy is evenly equivalent in both the type-1 and type-2 diabetes cases.
According to the CDC, diabetes is the most common cause of end stage renal disease (ESRD). In 2011, approximately 26 million of people in the United States were reported to have diabetes, and more than 200,000 people with end stage renal disease due to diabetes, were either on chronic renal dialysis or had a kidney transplant. Diabetic nephropathy is one of the common conditions among the diabetic individuals. All these factors are contributing to the impact of diabetic nephropathy across the globe.
This report by Mordor Intelligence provides extensive insights into the current scenario and growth prospects of the market studied. Detailed graphical representations of the pipeline landscape, based on various phases, and the status of clinical trials, across major regions of the world, are given, with data obtained from multiple sources. The report also comprises a list of key sponsors with pipeline products for the concerned market.
The report will cover analysis on trails and information on key sponsors, companies, and researchers.
Our data collection team builds scientific research models, based on data sourced from various internal databases, primary and secondary researches, and our in-house team of research experts. The pipeline assessment reports are generated based on information procured from various stakeholders, such as sponsors, clinical trial organizations, pharmaceutical companies, government bodies, trade agencies, industry journals, scientific literature databases, investor reports, press release statements, and several other sources. The data generated using secondary research and primary research is validated through discussions with industry KOL’s and C-suite executives. The data presented in the reports is continuously updated to incorporate the most relevant and authentic information to our clients.
2. Research Methodology
3. Disease Epidemiology and Trends
4. Healthcare Expenditure and R&D Trends
5. Executive Summary
6. Clinical Trials Segmentation by Phase
6.1 Phase-III Product Candidates
6.2 Phase-II Product Candidates
6.3 Phase-I Product Candidates
7. Clinical Trials, Segmentation by Status
8. Pipeline Therapeutic Assessment (Infographic Charts and a Brief Description)
8.1. By Clinical Phase and Molecule Type
8.2. By Clinical Phase and Route of Administration
8.3 By Sponsor/Collaborator/Institutions
8.4 By Geography
9. Market Updates
10. Key Sponsor Profiles
11. Sources and Disclaimer
12. About Mordor Intelligence